{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-25-000148","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.362854+00:00","generated_at":"2026-05-16T22:31:02.945686+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Immunovant Q2 loss $126.5M; batoclimab TED readout delayed to H1 2026; cash $521.9M","bullets":["Net loss $126.5M ($0.73/share) in fiscal Q2 ended Sep 30, 2025, vs $109.1M ($0.74) prior year.","Cash and equivalents $521.9M providing runway through GD readout expected in 2027.","Batoclimab Phase 3 TED: first readout delayed; both studies now expected to report concurrently H1 2026.","IMVT-1402 GD study showed first-ever potentially disease-modifying therapy with 6-month off-treatment data.","Topline results for IMVT-1402 in D2T RA and CLE expected 2026; GD, MG, D2T RA in 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-25-000148","json":"https://secwatch.observer/filing/0001764013-25-000148.json","markdown":"https://secwatch.observer/filing/0001764013-25-000148.md","text":"https://secwatch.observer/filing/0001764013-25-000148.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000148/0001764013-25-000148-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000148/imvt-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:31:02.945686+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}